PremiumCompany AnnouncementsKrystal Biotech Holds Annual Stockholders Meeting Krystal Biotech: Hold Rating Amid Slowed Growth and Conservative Pipeline Outlook Krystal Biotech price target lowered to $155 from $215 at Citi PremiumRatingsKrystal Biotech: Buy Rating Amid Temporary Revenue Dip and Promising Growth Prospects Krystal Biotech Reports Strong Q1 2025 Results Krystal Biotech’s Earnings Call Highlights Growth and Expansion PremiumCompany AnnouncementsKrystal Biotech Presents Promising Gene Therapy at ARVO KRYS Earnings Report this Week: Is It a Buy, Ahead of Earnings? Abeona approval does not change Krystal opportunity, says H.C. Wainwright 
